Porfimer sodium

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Porfimer sodium
Porfimer Sodium.png
Clinical data
AHFS/Drugs.com Consumer Drug Information
License data
  • US: C (Risk not ruled out)
Routes of
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability NA
Protein binding ~90%
Biological half-life 21.5 days (mean)
Excretion Fecal
CAS Number
PubChem CID
Chemical and physical data
Formula C68H74N8O11 (for n=0)
Molar mass 1179.36 g/mol (for n=0)
3D model (JSmol)
 NYesY (what is this?)  (verify)

Porfimer sodium, sold as Photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer.

Porfimer is a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units.[1] In practice, a red light source emitting at 630 nm is used to excite the Porfimer oligomers.[2]

Porfimer is Haematoporphyrin Derivative (HpD) (See PDT).

Approvals and indications[edit]

It was approved in Canada in 1993 for the treatment of bladder cancer.[2] It was approved in Japan in 1994 (for early stage lung cancer?).[2] It was approved by the U.S. FDA in December 1995 for esophageal cancer, and in 1998, it was approved for the treatment of early non-small cell lung cancer.[2]

In August 2003 the FDA approved its use for Barrett's esophagus.[3]


External links[edit]